 | • レポートコード：MRC2303I0015 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の無細胞タンパク質発現市場規模が、2021年に220.7百万ドルとなり、2027年に323.7百万ドルに達する見込みです。また、予測期間中（2022年〜2027年）に年平均6.52%で成長すると予測しています。本レポートは、無細胞タンパク質発現の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（付属品＆消耗品、溶解装置）分析、用途別（酵素工学、ハイスループット生産、タンパク質標識、タンパク質間相互作用、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Biotechrabbit GmbH、CellFree Sciences Co.,Ltd.、Cube Biotech GmbH、GeneCopoeia, Inc.、Jena Bioscience GmbH、Promega Corporation、Creative Biolabs、Merck KGaA、Takara Bio Inc.、Thermo Fisher Scientific Inc.、New England Biolabs、Bioneer Corporation、Otsuka Holding Co. Ltd. (Cambridge Isotope Laboratories Inc.)、LenioBio GmbH、Sutro Biopharma Inc、Addgene Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の無細胞タンパク質発現市場規模：製品別 - 付属品＆消耗品の市場規模 - 溶解装置の市場規模 ・世界の無細胞タンパク質発現市場規模：用途別 - 酵素工学における市場規模 - ハイスループット生産における市場規模 - タンパク質標識における市場規模 - タンパク質間相互作における市場規模 - その他用途における市場規模 ・世界の無細胞タンパク質発現市場規模：地域別 - 北米の無細胞タンパク質発現市場規模 アメリカの無細胞タンパク質発現市場規模 カナダの無細胞タンパク質発現市場規模 メキシコの無細胞タンパク質発現市場規模 … - ヨーロッパの無細胞タンパク質発現市場規模 ドイツの無細胞タンパク質発現市場規模 イギリスの無細胞タンパク質発現市場規模 フランスの無細胞タンパク質発現市場規模 … - アジア太平洋の無細胞タンパク質発現市場規模 中国の無細胞タンパク質発現市場規模 日本の無細胞タンパク質発現市場規模 インドの無細胞タンパク質発現市場規模 … - 中東/南米の無細胞タンパク質発現市場規模 南アフリカの無細胞タンパク質発現市場規模 ブラジルの無細胞タンパク質発現市場規模 アルゼンチンの無細胞タンパク質発現市場規模 … - その他地域の無細胞タンパク質発現市場規模 ・競争状況 ・市場機会・将来の動向 |
The global cell-free protein expression market is estimated to be USD 220.7 million in 2021. It is expected to reach USD 323.7 million by 2027, registering a CAGR of 6.52 % from 2022 to 2027.
The market has a slightly positive impact due to the pandemic. Moreover, according to the article, “Harnessing proteomics could improve therapeutic approaches to COVID-19,” published in November 2020, the development of therapeutic and preventive strategies requires an accurate understanding of proteins’ role in the SARS-CoV-2 infection process and progression of COVID-19.
Furthermore, according to the article, “Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery,” published in November 2021, Therapeutic monoclonal antibodies developed against the spike protein of SARS-CoV-2 have become a promising intervention to treat severely ill coronavirus disease 2019 (COVID-19) patients. However, the isolation, evaluation, and identification of the best antibody candidate require a series of time-consuming and labor-intensive experiments, including cloning, transfection, cell-based protein expression, protein purification, and critical assessment.
The significant factors for the growth of the cell-free protein expression market include the increasing R&D in proteomics and genomics, high prevalence of cancer and infectious diseases, and shorter-expression time and structural modification. Cell-free protein expression employs cell lysates to produce the desired recombinant proteins. The primary advantage of this technique is the aversion of workflow hurdles of maintaining cell culture or living cells. Cell lysates are produced by the breakdown and use of cellular components of eukaryotic or bacterial cells. Several cell-free protein expression systems are currently commercially available, based on E. coli, rabbit reticulocytes, wheat germs, human cell lines, and insect cells.
According to the article, “Exploring the Potential of Cell-Free Protein Synthesis for Extending the Abilities of Biological Systems,” published in October 2019, Cell-free protein synthesis (CFPS) has the potential to overcome loopholes in the current in vivo production systems and is a promising tool in both primary and applied scientific research. It facilitates a simplified organization of desired experiments with various reaction conditions, making CFPS a powerful tool in biological research. It has been used to expand genetic code, assembly of viruses, and metabolic engineering to produce toxic and complex proteins. Subsequently, CFPS systems have emerged as a powerful technology for the high-throughput production of membrane proteins, enzymes, and therapeutics.
An in vitro protein expression system has significant advantages over living cell-based protein expression, including a shorter duration of the process, isotopic labeling of proteins, incorporation of non-natural amino acids, and optimization of protein complexes. In addition, the ability to enable high throughput production, the recent trend of more research in personalized medicine, and the growing need for biological therapies to manage cancer is significant driver for the adoption of cell-free protein expression techniques by pharmaceutical and biotechnology firms.
Cell-free Protein Expression Market Trends
The E. Coli Lysate Segment of the Lysate Systems is Expected to be the Fastest Growing Segment Over the Forecast Period
E. coli lysates are the most commonly used systems among all available commercial lysate systems. E. coli lysates are devoid of endogenous genetic messages and have advantages, such as very high protein yield and tolerability to most additives. Furthermore, E. coli-based systems are being used in recombinant techniques for the manufacture of various biological therapeutics and insulin. Continuous use has enabled research on interactions and tolerability of the byproducts of E. coli-based systems, and significant present scientific literature enables its rapid adoption by industries and academics.
In E. coli-based systems, codons used are different, with some being eukaryotic specific. Additionally, post-translational modifications are not possible, which in turn, limit the system’s usage in the synthesis of specific human therapeutics. Significant advancements have been, however, made in order to address these problems. Therefore, the E. coli lysate sub-segment is expected to register a steady growth rate during the forecast period, owing to high adoption rates and recent developments.
North America Dominates the Market, and It is Expected to do Same in the Forecast Period
North America is found to hold a major share in the cell-free protein expression market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. The primary factors behind the large market size include the increasing prevalence of chronic diseases, such as cancer, aging population, growing demand for targeted and personalized medicine, the presence of major R&D facilities, and favorable government initiatives in the United States. There is a growing trend of cell-based research in the US academia and biotechnology industries. In recent years, several government initiatives have been supplementing the growth of the cell-free protein expression market in the United States.
In the North American region, the United States holds the largest market share due to factors such as the increasing burden of cancer cases in the country, which is anticipated to stimulate the demand for cell-free protein expression market.
According to Globocan 2020, an estimated 2,281,658 new cancer cases were diagnosed in 2020, and 612390 cancer deaths were reported in the United States. The increasing demand and acceptance of cell-free protein expression in the treatment of diseases such as cancer, rare diseases, and other disorders are also driving the growth of the studied market in the region.
Cell-free Protein Expression Market Competitor Analysis
The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some of the market players are biotechrabbit GmbH, CellFree Sciences Co. Ltd, Cube Biotech GmbH, GeneCopoeia Inc., Jena Bioscience GmbH, Promega Corporation, Qiagen NV, Sigma-Aldrich Corporation (Merck KGaA), Takara Bio Inc., and Thermo Fisher Scientific Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D in the Fields of Proteomics and Genomics
4.2.2 Growing Burden of Cancer and Infectious Diseases
4.2.3 Shorter Expression Time and Structural Modification
4.3 Market Restraints
4.3.1 High Cost of Protein Expression Systems
4.3.2 Lack of Effective Systems for Post-translational Modifications
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Products
5.1.1 Accessories and Consumables
5.1.2 Lysate Systems
5.1.2.1 E. Coli Lysate
5.1.2.2 Wheat Germ Extract Lysate
5.1.2.3 Rabbit Reticulocyte Lysate
5.1.2.4 Insect Cell Lysate
5.1.2.5 Human Cell Lysate
5.1.2.6 Other Lysate Systems
5.2 By Application
5.2.1 Enzyme Engineering
5.2.2 High Throughput Production
5.2.3 Protein Labeling
5.2.4 Protein-Protein Interaction
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biotechrabbit GmbH
6.1.2 CellFree Sciences Co.,Ltd.
6.1.3 Cube Biotech GmbH
6.1.4 GeneCopoeia, Inc.
6.1.5 Jena Bioscience GmbH
6.1.6 Promega Corporation
6.1.7 Creative Biolabs
6.1.8 Merck KGaA
6.1.9 Takara Bio Inc.
6.1.10 Thermo Fisher Scientific Inc.
6.1.11 New England Biolabs
6.1.12 Bioneer Corporation
6.1.13 Otsuka Holding Co. Ltd. (Cambridge Isotope Laboratories Inc.)
6.1.14 LenioBio GmbH
6.1.15 Sutro Biopharma Inc
6.1.16 Addgene Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS